Business Wire: May 16, 2017 – PARIS, France – Final 5-year outcomes from the DIRECT first-in-man study were presented at the EuroPCR symposium today, with 0% clinically driven target lesion revascularization (TLR), target vessel failure (TVF), and major adverse cardiac events (MACE) reported. The…
